More articles from Hematologic Malignancies

You have access
Diffuse diseases and comprehensive tests- PET/CT in Multisystem Langerhans celll Histiocytosis.
Suraj Kumar, Dikhra Khan, Sambit Sagar, Rachna Seth, Kritin Shankar, Anushna Babu, Arunraj Sreedharan Thankarajan, Khangembam Bangkim Chandra and Rakesh Kumar

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3131;
You have access
Prognostic Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial
Lutz van Heek, Colin Stuka, Horst Müller, Helen Kaul, Jasmin Mettler, Felicitas Hitz, Christian Baues, Michael Fuchs, Peter Borchmann, Conrad-Amadeus Voltin, Andreas Engert, Markus Dietlein and Carsten Kobe

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3118;
You have access
Series interim 18F-FDG PET/CT stratify the prognosis of patients with Hodgkin lymphoma: based on Peking Criteria
maomao wei, xuetao chen, Tingting Yuan, Xinfeng Lin and xuejuan wang

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3122;
You have access
Prognostic value of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 Trial
Cyrille Morvant, Clement Bailly, Thomas Carlier, Gauthier FRECON, Francoise Kraeber-Bodere, Steven Le Gouill, Elizabeth Macintyre and Caroline Bodet-Milin

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3126;
You have access
Stratification of Hodgkin lymphoma patients using metabolic tumor burden and tumor dissemination calculated from baseline [18F]FDG-PET/CT imaging
Kibrom Girum, Anne-Ségolène Cottereau, David Haberl, Laszlo Papp, Louis Rebaud, Marcus Hacker, Thomas Beyer, Alexander Haug, Ignasi Carrió and Irene Buvat

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3123;
You have access
Role of Fluorodeoxyglucose Positron emission tomography/computed tomography and PET/CT guided directed core needle biopsy during the different management stages of lymphoma
Rajender Kumar, Venkata Krishnaraju, Bhagwant Mittal, Anish Bhattacharya, Harmandeep Singh and Gaurav Prakash

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3130;
You have access
The diagnostic value of 18F-FDG PET/MR in Langerhans histiocytosis in children
Fangxiao Wang and Yuanfan Xu

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3129;
You have access
Parameters on F-18 FDG PET/CT which predict treatment response and survival in paediatric and adolescent Hodgkin Lymphoma.
Janet Reed

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3119;
You have access
Inclusion of baseline FDG PET/CT and clinical data for an improved predictive risk model in non-Hodgkin lymphoma patients treated using CAR T-cell therapy
Lisa Schmidt, John Crandall, Temitope Agabalogun, Ashwin Singh Parihar and Richard Wahl

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3133;
You have access
Testosterone replacement therapy (TRT) is associated with significant decline in testicular 18F-FDG activity in hypogonadal male patients with Erdheim Chester Disease (ECD).
Georgios Z. Papadakis, Jorge Irizarry-Caro, Skand Shekhar, Rachel Wurth, Amit Tirosh, Sara Haroutunian, Bernadette Gochuico, William Gahl, Juvianee Estrada-Veras, Kevin O'Brien and Fady Hannah-Shmouni

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3132;

Main menu

User menu

Search

More articles from Hematologic Malignancies

Pages